Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

135.63USD
10:52am EST
Change (% chg)

$0.33 (+0.24%)
Prev Close
$135.30
Open
$136.25
Day's High
$138.47
Day's Low
$134.97
Volume
325,904
Avg. Vol
2,654,307
52-wk High
$163.71
52-wk Low
$109.12

Select another date:

Mon, Jan 9 2017

BRIEF-Alexion interim CEO says company is not up for sale - conf

* Alexion interim CEO says they are not up for sale - JPM Healthcare conf

BRIEF-Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis

* Alexion submits U.S. and EU applications seeking approval of Soliris (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis (gMG)

BRIEF-FDA grants orphan drug designation to ALXN1210

* FDA grants orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh)

Alexion says no need to revise earnings, shares rise

Alexion Pharmaceuticals Inc on Wednesday filed its delayed third-quarter 2016 financial report with U.S. regulators and said an investigation into allegations regarding sales practices found no need to restate previous financial results.

Alexion Pharmaceuticals says CEO, CFO resign, shares slump

Alexion Pharmaceuticals Inc's chief executive officer and chief financial officer resigned, a month after the drugmaker said it was investigating allegations related to sales practices of its flagship drug.

BRIEF-Alexion Pharmaceuticals announces new data

* Alexion Pharmaceuticals Inc - new data from an analysis of patients enrolled in global atypical hemolytic uremic syndrome (aHUS) registry

BRIEF-Paulson & Co cuts share stake in Alexion Pharmaceuticals, Johnson & Johnson

* Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227,700 shares

BRIEF-Alexion says new long-term data show reduction in liver fibrosis and cirrhosis in cohort of patients with lysosomal acid lipase deficiency treated with Kanuma

* Alexion says new long-term data show reduction in liver fibrosis and cirrhosis in cohort of patients with lysosomal acid lipase deficiency treated with Kanuma

BRIEF-Alexion Pharmaceuticals files for non-timely 10-Q

* Files for non-timely 10-Q Source text for Eikon: [ID:http://bit.ly/2fTifZm] Further company coverage:

UPDATE 1-Alexion says investigating Soliris sales practices

Nov 10 Alexion Pharmaceuticals Inc said on Wednesday it was investigating allegations made by a former employee regarding sales practices involving its flagship and costly blood disorder drug Soliris.

Select another date: